首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients.
【24h】

Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients.

机译:胸腺嘧啶核苷标记与126名乳腺癌患者的Ki-67增殖指数之间的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Proliferative activity has been proposed as a prognostic and predictive marker for breast cancer; Ki-67 is one of the most frequently used markers to assess proliferative activity. In the current study, Ki-67 immunoreactivity was comparatively assessed, even in terms prognostic relevance, with 3H-thymidine labeling index as a reference standard for proliferation in 126 patients with stage I and II breast cancer. There was a significant but weak correlation between Ki-67 values and the 3H-thymidine labeling index (r = 0.19, P = 0.03). Analysis of variance showed that the mean 3H-thymidine labeling index values were not statistically different in terms of pathologic size (T1, T2. T3, T4), number of pathologically positive axillary nodes (neg, pos 1-3, pos > 3), and grading classes (1, 2, 3), but significantly and inversely correlated with estrogen receptor status (P = 0.033) and progesterone receptor status (P = 0.08). The Ki-67 values significantly correlated with N status (P = 0.041), estrogen receptorstatus (P < 0.001), progesterone receptor status (P < 0.001), and grading (P < 0.001). The median follow-up was 37 months. In terms of prognosis, Ki-67 was associated significantly with overall survival (P = 0.01) and marginally with disease-free survival (P = 0.095). A significant difference in prognosis was found for both disease-free survival (P = 0.024) and overall survival (P = 0.040) when a 3H-thymidine labeling index cut-off of 6.5% was used (P = 0.024). The results suggest that, although both are indicators of proliferative activity, 3H-thymidine labeling index and Ki-67 seem to identify breast cancers with different phenotypes.
机译:已经提出增殖活性可以作为乳腺癌的预后和预测指标。 Ki-67是评估增殖活性最常用的标记之一。在本研究中,以3H-胸腺嘧啶核苷标记指数作为126例I和II期乳腺癌患者增殖的参考标准,对Ki-67免疫反应性(甚至在预后相关性方面)进行了比较评估。 Ki-67值与3H-胸苷标记指数之间存在显着但弱的相关性(r = 0.19,P = 0.03)。方差分析表明,平均3H-胸腺嘧啶核苷标记指数值在病理学大小(T1,T2.T3,T4),病理学阳性的腋窝淋巴结数目(阴性,位置1-3,位置> 3)方面无统计学差异。 ,分级等级(1、2、3),但与雌激素受体状态(P = 0.033)和孕激素受体状态(P = 0.08)呈显着负相关。 Ki-67值与N状态(P = 0.041),雌激素受体状态(P <0.001),孕激素受体状态(P <0.001)和分级(P <0.001)显着相关。中位随访时间为37个月。在预后方面,Ki-67与总体生存率显着相关(P = 0.01),与无病生存率相关性很小(P = 0.095)。当使用6.5%的3H-胸苷标记指数截止值(P = 0.024)时,无病生存期(P = 0.024)和总生存期(P = 0.040)的预后都有显着差异。结果表明,尽管两者都是增殖活性的指标,但3H-胸苷标记指数和Ki-67似乎可以鉴定出具有不同表型的乳腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号